Advertisement

Related Videos

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Lymphoma

The ASCO Post Staff

Mark J. Ratain, MD, on Chronic Lymphocytic Leukemia: Making a Case for Low-Dose Ibrutinib

Mark J. Ratain, MD, of the University of Chicago, talks about why ibrutinib—which can lead to cardiotoxicities—should be studied at a lower dose for patients with chronic lymphocytic leukemia. Data suggest a reduced dose may prevent dose interruption due to adverse events and may have a better therapeutic index.

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Advertisement

Advertisement




May
04
Today In Oncology
Addition of Perioperative Pembrolizumab to Standard of Care in Newly Diagnosed Locally Advanced Head and Neck Cancer
Dose Escalation of Fluorodeoxyglucose PET Guided Radiotherapy for Locally Advanced NSCLC
Use of CAD CAM May Improve Jaw Reconstruction Outcomes Among Patients With Head and Neck Cancer
Adavosertib in Recurrent or Persistent Uterine Serous Carcinoma
Applications Are Now Open for the 2025 Integrative Oncology Scholars Program and Integrative Oncology Fellows Program
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo